Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).

June 16, 14:00 CEST/8:00 AM ET

Register and attend
CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Increase of Number of Shares and Votes in Hansa Medical AB (publ)

31 Oct 2018, 08:00
Regulatory information
Lund, Sweden, October 31, 2018 - Hansa Medical AB (NASDAQ Stockholm:HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of October 2018. 

As previously announced on September 6, 2018. Hansa’s board of directors resolved to issue 391,503 class C shares, by virtue of authorization by the general meeting held on May 29, 2018. Furthermore, the Hansa general meeting resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 50,000 ordinary shares have been issued.

All class C shares are owned by the Company. The share issue forms part of the Company’s long-term incentive program, and the purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018.

As of today, the total number of registered and outstanding shares of Hansa amounts to 38,904,889, whereof 38,183,125 are ordinary shares and 721,764 are class C shares. As of today, the number of votes in Hansa amounts to 38,255,301.4, and the registered share capital amounts to SEK 38,904,889.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00am CET on October 31, 2018.

Files

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477
E-mail: [email protected]

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert 
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902

About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.